CLAIMS

1. A pharmaceutical complex preparation in a single-layer tablet for preventing or treating cardiovascular diseases, the pharmaceutical complex preparation comprising, as active ingredients, amlodipine or a pharmaceutically acceptable salt thereof, chlorthalidone or a pharmaceutically acceptable salt thereof, and losartan or a pharmaceutically acceptable salt thereof, wherein amlodipine or a pharmaceutically acceptable salt thereof is comprised in an amount of 0.5 mg to 5 mg when converted to an amlodipine free base form, and wherein losartan or a pharmaceutically acceptable salt thereof is comprised in an amount of 7 mg to 30 mg when converted to a losartan free acid form.

2. The pharmaceutical complex preparation in a single-layer tablet of claim 1, wherein chlorthalidone or a pharmaceutically acceptable salt thereof is comprised in an amount of 1 mg to 7 mg when converted to a chlorthalidone free base form.

3. The pharmaceutical complex preparation in a single-layer tablet of claim 1, wherein amlodipine or a pharmaceutically acceptable salt thereof, chlorthalidone or a pharmaceutically acceptable salt thereof, and losartan or a pharmaceutically acceptable salt thereof are comprised in a mixed granular part.

4. The pharmaceutical complex preparation in a single-layer tablet of claim 1, wherein a total weight of the pharmaceutical complex preparation in a single-layer tablet for preventing or treating cardiovascular diseases is less than or equal to 350 mg.

5. The pharmaceutical complex preparation in a single-layer tablet of claim 1, wherein a total weight of the pharmaceutical complex preparation in a single-layer tablet for preventing or treating cardiovascular diseases is greater than or equal to 70 mg and less than or equal to 350 mg.

6. The pharmaceutical complex preparation in a single-layer tablet of claim 1, wherein a total weight of the active ingredients, such as amlodipine or a pharmaceutically acceptable salt thereof, chlorthalidone or a pharmaceutically acceptable salt thereof, and losartan or a pharmaceutically acceptable salt thereof, in the complex preparation is greater than or equal to 15 mg.

7. The pharmaceutical complex preparation in a single-layer tablet of claim 1, wherein the active ingredients are comprised in an amount of 10 % or more of the total weight of the complex preparation.

8. The pharmaceutical complex preparation in a single-layer tablet of claim 1, wherein the active ingredients are comprised in an amount of 20 % or more of the total weight of the complex preparation.

9. The pharmaceutical complex preparation in a single-layer tablet of claim 1, further comprising a disintegrant, wherein an amount of the disintegrant is 1 % to 15 % of the total weight of the complex preparation.

10. The pharmaceutical complex preparation in a single-layer tablet of claim 1, further comprising a disintegrant, wherein an amount of the disintegrant is 4 % to 15 % of the total weight of the complex preparation.

11. The pharmaceutical complex preparation in a single-layer tablet of claim 1, further comprising a disintegrant, wherein an amount of the disintegrant is 9 % to 15 % of the total weight of the complex preparation.

12. The pharmaceutical complex preparation in a single-layer tablet of claim 1, further comprising a pharmaceutical additive selected from a diluent, a disintegrant, a lubricant, and a combination thereof.

13. The pharmaceutical complex preparation in a single-layer tablet of claim 12, wherein the diluent is any one selected from microcrystalline cellulose, starch, pre-gelatinized starch, dicalcium phosphate (DCP), lactose, low-substituted hydroxypropyl cellulose, and a combination thereof.

14. The pharmaceutical complex preparation in a single-layer tablet of claim 12, wherein the disintegrant is any one selected from crospovidone, croscarmellose sodium, sodium starch glycolate, starch, pre-gelatinized starch, and a combination thereof.

15. The pharmaceutical complex preparation in a single-layer tablet of claim 14, wherein the lubricant is any one selected from magnesium stearate, palmitic acid, talc, magnesium stearate, zinc stearate, calcium stearate, and a combination thereof.

16. The pharmaceutical complex preparation in a single-layer tablet of claim 1, further comprising, as diluents, microcrystalline cellulose and low-substituted hydroxypropyl cellulose, wherein a weight ratio of microcrystalline cellulose to low-substituted hydroxypropyl cellulose is 2:1 to 1:1.

17. The pharmaceutical complex preparation in a single-layer tablet of claim 1, wherein a dissolution rate of amlodipine in 30 minutes is greater than or equal to 80 % when a dissolution test is performed on the complex preparation according to the guidelines for setting dissolution specifications for oral drugs.

18. The pharmaceutical complex preparation in a single-layer tablet of claim 1, wherein a dissolution rate of chlorthalidone in 30 minutes is greater than or equal to 80 % when a dissolution test is performed on the complex preparation according to the guidelines for setting dissolution specifications for oral drugs.

19. The pharmaceutical complex preparation in a single-layer tablet of claim 1, wherein a dissolution rate of losartan in 30 minutes is greater than or equal to 80 %

when a dissolution test is performed on the complex preparation according to the guidelines for setting dissolution specifications for oral drugs.